en · de · es · fr · pt
sr9009-notes.peptides7250.com › News › Identity, Handling, And Regulation — Field Notes

Identity, Handling, And Regulation — Field Notes

By Editorial Desk · published 2026-02-05 · last reviewed 2026-03-05 · News

Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white solidVisual inspection is not sufficient for identity.
SolubilitySoluble in DMSO and ethanolLow solubility in water.
Typical storage-20 °C, desiccated, darkProtect from repeated temperature changes.
Common analytical methodLC-MS or HPLC-UVReference standard required for comparison.
Common synonymsSR9009; Stenabolic; REV-ERB agonistVendor naming may vary.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Related pages on this site

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Notes from published material

== Effects against senescent cells == In animal studies, navitoclax was found to be a senolytic agent, inducing apoptosis in senescent, but not non-senescent cells. Oral administration of navitoclax (ABT-263) to either sublethally irradiated or normally aged mice reduced senescent cells, including senescent bone marrow hematopoietic stem cells and senescent muscle stem cells. This depletion mitigated total-body irradiation-induced premature aging of the hematopoietic system and rejuvenated the aged hematopoietic stem cells and muscle stem cells in normally aged mice. On September 19, 2018, an article was published in Nature about using navitoclax to kill senescent glial cells in mice. The drug had a protective effect against memory loss in mice genetically engineered to simulate Alzheimer's disease. On December 3, 2024, an article was published in Aging detailing a study investigating the effects of topical navitoclax (ABT-263) on aged mouse skin. It examined whether eliminating senescent cells could improve wound healing. In the study, 24-month-old mice were treated with topical navitoclax (ABT-263) for five days. The treatment reduced the expression of senescence markers p16 and p21 and decreased the number of SA-β-gal– and p21-positive cells compared with DMSO controls. Navitoclax (ABT-263) application also induced a transient inflammatory response and macrophage infiltration. Bulk RNA sequencing revealed upregulation of genes involved in wound-healing pathways, including inflammation, angiogenesis, collagen synthesis, and extracellular matrix remodeling.

== Fictional spy stories == Cloak and dagger stories became part of the popular culture of the Cold War in both East and West, with innumerable novels and movies that showed how polarized and dangerous the world was. Soviet audiences were thrilled by spy stories showing how their KGB agents protected the motherland by foiling dirty work by the intelligence agencies of the United States, United Kingdom, and Israel. After 1963, Hollywood increasingly depicted the CIA as clowns (as in the comedy TV series Get Smart) or villains (as in Oliver Stone's 1992 film JFK). Ian Fleming's infamous spy novels about the MI6 agent James Bond also referenced elements of the Cold War when being adapted into films. One example of this includes the first Bond film, Dr. No, which was released in 1962 and used the Cuban Missile Crisis as a plot base. However, Cuba was substituted for Jamaica in the film.

== Politics == In Western culture, references to tofu have been used as a pejorative shorthand against left wing and vegan ideologies. In 2018, US Republican Ted Cruz criticized Democrats for wanting Texas to become "just like California, right down to tofu and silicon and dyed hair". In 2022, British home secretary Suella Braverman attacked the "Guardian-reading, tofu-eating wokerati" in the British House of Commons, blaming them for obstructing the roads. In April 2025 Markus Söder, the head of the German Christian Social Union, said that Germany could now look forward to more Leberkäse—a kind of meatloaf—instead of "Tofu-mania".

=== Career statistics === In a nine-season career, Mizell had a 90–88 record with a 3.85 ERA in 268 games, 230 of which were starts. He pitched 61 complete games, including 15 shutouts. Mizell allowed 654 earned runs and struck out 918, walking 680 in 1,528+2⁄3 innings pitched. He enjoyed his greatest success against the Pirates, against whom he went 14–7. Mizell also won 14 of his first 17 decisions against the Cubs, but Chicago did better against him later in his career, winning 12 of their final 16 decisions against him. Writing in 1971, Ray Owen, sports editor for The Southeast Missourian, called Mizell "one of the best strikeout hurlers around the National League scene for a span of ten years."

Sources: en.wikipedia.org

Background from the literature

In addition to writing fiction, Tolkien was an author of academic literary criticism. His seminal 1936 lecture, later published as an article, revolutionized the treatment of the Anglo-Saxon epic Beowulf by literary critics. The essay remains highly influential in the study of Old English literature to this day. Beowulf is one of the most significant influences upon Tolkien's later fiction, with major details of both The Hobbit and The Lord of the Rings being adapted from the poem.

Max Vasmer's etymological dictionary traces the name to the Tatar Turkic word kazak, kozak, in which cosac meant 'free man' but also 'conqueror'. The ethnonym Kazakh is from the same Turkic root. In written sources, the name is first attested in the Codex Cumanicus from the 13th century. Larysa Pritsak (2024) grouped the earliest references of the word Cossack(s) into three groups:

== External links == MedlinePlus Encyclopedia: Gamma-glutamyl transpeptidase (GGT) blood test gamma-Glutamyltransferase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) GGT - Lab Tests Online Overview of all the structural information available in the PDB for UniProt: P19440 (Gamma-glutamyltransferase 1) at the PDBe-KB.

While the Ramachandran plot has been a textbook resource for explaining the structural behavior of peptide bond, an exhaustive exploration of how a peptide behaves in every region of the Ramachandran plot was only recently published (Mannige 2017). The Molecular Biophysics Unit at Indian Institute of Science celebrated 50 years of Ramachandran Map by organizing International Conference on Biomolecular Forms and Functions from 8–11 January 2013.

== Terminology == There is no consensus among historians about whether terms such as "unfree labourer" or "enslaved person", rather than "slave", should be used when describing the victims of slavery. According to those proposing a change in terminology, slave perpetuates the crime of slavery in language by reducing its victims to a nonhuman noun instead of "carry[ing] them forward as people, not the property that they were" (see also People-first language). Other historians prefer slave because the term is familiar and shorter, or because it accurately reflects the inhumanity of slavery, with person implying a degree of autonomy that slavery does not allow.

Sources: en.wikipedia.org

Further detail

Innate immune response cells such as dendritic cells engulf pathogens through a process called phagocytosis. Dendritic cells then migrate to the lymph nodes where T cells (adaptive immune cells) wait for signals to trigger their activation. In the lymph nodes, dendritic cells mince the engulfed pathogen and then express the pathogen clippings as antigen on their cell surface by coupling them to a special receptor known as a major histocompatibility complex. T cells can then recognize these clippings and undergo a cellular transformation resulting in their own activation. γδ T cells possess characteristics of both the innate and adaptive immune responses. Macrophages can also activate T cells in a similar approach (but do not do so naturally). This process carried out by both dendritic cells and macrophages is termed antigen presentation and represents a physical link between the innate and adaptive immune responses. Upon activation, mast cells release heparin and histamine to effectively increase trafficking to and seal off the site of infection to allow immune cells of both systems to clear the area of pathogens. In addition, mast cells also release chemokines which result in the positive chemotaxis of other immune cells of both the innate and adaptive immune responses to the infected area. Due to the variety of mechanisms and links between the innate and adaptive immune response, an adjuvant-enhanced innate immune response results in an enhanced adaptive immune response.

== External links == Institute of Biological Chemistry, Academia Sinica Institute of Biochemical Sciences, National Taiwan University Register of the Choh Hao Li Papers, 1937-1987, Online Archive of California Li, Choh Hao, Social Networks and Archival Context Choh Hao Li Papers – University of California, San Francisco Library, Archives and Special Collections Biography and chronology Forgotten Superheroes of Science and Medicine: Choh Hao Li History of UCSF biography Short biography R. David Cole, "Choh Hao Li", Biographical Memoirs of the National Academy of Sciences (1996)

== Career == Beginning in the late 1970s, at Columbia University, Wigler, Richard Axel and Saul Silverstein developed methods for engineering animal cells. These methods are the basis for many discoveries in mammalian genetics, and the means for producing protein therapeutics such as those used to treat heart disease, cancer and strokes. After moving to CSHL, Wigler continued his studies of gene transfer into mammalian cells, exploring the integration of foreign DNA and its stability of expression in host cells, demonstrating the inheritance of DNA methylation patterns, and isolating the first vertebrate genes, and first human oncogenes, using DNA transfer and genetic selection. His laboratory was among the group that first showed the involvement of members of the RAS gene family in human cancer, and that point mutations can activate the oncogenic potential of cellular genes. Wigler's laboratory was the first to demonstrate that some regulatory pathways have been so conserved in evolution that yeast can be used as a host to study the function of mammalian genes and in particular genes involved in signal transduction pathways and cancer. This led to deep insights into RAS function, eventually solving the RAS biochemical pathway in yeast and humans, and demonstrating the multifunctional nature of this important oncogene. From this work in fungi new cellular mechanisms were recognized for "insulating" signal transduction pathways with protein scaffolds that reduce cross-talk and for processing and localization of proteins.

=== Chemical === The chemistry of mendelevium is known largely in solution (as available quantities do not allow the creation of pure compounds), in which it can take on the +3 or +2 oxidation states. The +1 state has also been reported, but has not yet been confirmed. Before mendelevium's discovery, Seaborg and Katz predicted that it should be predominantly trivalent in aqueous solution and hence should behave similarly to other tripositive lanthanides and actinides. After the synthesis of mendelevium in 1955, these predictions were confirmed, first in the observation at its discovery that it eluted just after fermium in the trivalent actinide elution sequence from a cation-exchange column of resin, and later the 1967 observation that mendelevium could form insoluble hydroxides and fluorides that coprecipitated with trivalent lanthanide salts. Cation-exchange and solvent extraction studies led to the conclusion that mendelevium was a trivalent actinide with an ionic radius somewhat smaller than that of the previous actinide, fermium. Mendelevium can form coordination complexes with 1,2-cyclohexanedinitrilotetraacetic acid (DCTA). In reducing conditions, mendelevium(III) can be easily reduced to mendelevium(II), which is stable in aqueous solution. The standard reduction potential of the E°(Md3+→Md2+) couple was variously estimated in 1967 as −0.10 V or −0.20 V: later 2013 experiments established the value as −0.16±0.05 V. In comparison, E°(Md3+→Md0) should be around −1.74 V, and E°(Md2+→Md0) should be around −2.5 V.

== Function and clinical significance == Short 'oligopeptides', predominantly smaller than 30 amino acids in length, play essential roles as hormones, in the surveillance against pathogens, and in neurological activities. Therefore, these molecules constantly need to be specifically generated and inactivated, which is the role of the oligopeptidases. Oligopeptidase is a term coined in 1979 to designate a sub-group of the endopeptidases, which are not involved in the digestion nor in the processing of proteins like the pancreatic enzymes, proteasomes, cathepsins among many others. The prolyl-oligopeptidase or prolyl endopeptidase (POP) is a good example of how an oligopeptidase interacts with and metabolizes an oligopeptide. The peptide has first to penetrate into a 4 Å hole on the surface of the enzyme in order to reach an 8,500Å3 internal cavity, where the active site is located. Even though the size of the peptide is crucial for its docking, the flexibility of both enzyme and ligand seems to play an essential role in determining whether a peptide bond will be hydrolyzed or not. This contrasts with the classical specificity of proteolytic enzymes, which derives from the chemical features of the amino acid side chains around the scissile bond. A number of enzymatic studies supports this conclusion. This peculiar specificity suggests that the concept of conformational melding of the peptides used to explain the interaction between T-cell receptor and its epitopes, seems more likely to describe the enzymatic specificity of the oligopeptidases.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

What storage conditions are typical?

The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.

Is SR9009 legal to purchase?

Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network